Chronic Myeloid Leukemia

FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia
May 05, 2020

The FDA granted orphan drug designation to Ascentage Pharma’s HQP1351 for the treatment of chronic myeloid leukemia.

Value of Second-Generation TKIs Must Be Considered for CML Patients
June 24, 2019

Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia.

Updated Results Show Ongoing Treatment-Free Remission in CML Trial
June 06, 2019

Updated results from ENESTop show patients with CML remain in treatment-free remission after stopping nilotinib.